7 days Vertex Gears Up to Report Q3 Earnings: Is a Beat in the Cards?Zacks
VRTX’s revenues in the third quarter of 2024 are likely to have been driven by the robust sales of its lead CF product, Trikafta/Kaftrio.
Earnings · Pharmaceuticals · Vertex (VRTX)
X